Wednesday, September 28, 2016 2:29:15 AM
Chronological Insider Trades
This section gives a chronological listing of the insider trading activity of executive officers within Palatin Technologies Inc. From left to right, the columns give the details of the transactions by showing the name and title of
the person who made the transaction on a particular date. It further shows that they bought or sold a certain number of shares at a particular price through a certain type of transaction. Finally, it shows what percent of the
person's holdings were traded and how many shares the person held once the transaction was complete.
Name, Title
Transaction
Transactions
During 2016
# of Shares
Price($)
Type
% of Holdings Traded
Now Holds
Spana, Carl, CEO
Bought
09/07
290,000
0.00
Direct, Non Open Market
14.4
2,011,079
Wills, Stephen T., CFO
Bought
09/07
268,000
0.00
Direct, Non Open Market
14.5
1,842,041
Spana, Carl, CEO
Bought
06/27
87,500
0.00
Direct, Non Open Market
5.0
1,758,020
Spana, Carl, CEO
Sold
06/27
32,594
0.45
Direct, Non Open Market
1.9
1,725,426
Wills, Stephen T., CFO
Bought
06/27
75,000
0.00
Direct, Non Open Market
4.7
1,601,203
Wills, Stephen T., CFO
Sold
06/27
22,815
0.45
Direct, Non Open Market
1.4
1,578,388
Deveer, Robert K., Jr., DIR
Bought
06/13
20,000
0.00
Direct, Non Open Market
6.8
294,685
Dunton, Alan W., DIR
Bought
06/13
20,000
0.00
Direct, Non Open Market
10.2
195,645
Hull, Joseph Stanley, DIR
Bought
06/13
20,000
0.00
Direct, Non Open Market
7.5
265,625
Morris, Arlene, DIR
Bought
06/13
20,000
0.00
Direct, Non Open Market
24.8
80,625
Prendergast, John K.A., DIR
Bought
06/13
40,000
0.00
Direct, Non Open Market
8.6
466,767
Rossetti, Angela, DIR
Bought
06/13
20,000
0.00
Direct, Non Open Market
14.2
140,625
Spana, Carl, CEO
Bought
06/13
105,000
0.00
Direct, Non Open Market
6.7
1,559,339
Spana, Carl, CEO
Sold
06/13
38,819
0.49
Direct, Non Open Market
2.5
1,520,520
Wills, Stephen T., CFO
Bought
06/13
95,000
0.00
Direct, Non Open Market
6.7
1,421,352
Wills, Stephen T., CFO
Sold
06/13
28,899
0.49
Direct, Non Open Market
2.0
1,392,453
Deveer, Robert K., Jr., DIR
Bought
06/09
37,500
0.00
Direct, Non Open Market
13.7
274,685
Dunton, Alan W., DIR
Bought
06/09
37,500
0.00
Direct, Non Open Market
21.3
175,645
Hull, Joseph Stanley, DIR
Bought
06/09
37,500
0.00
Direct, Non Open Market
15.3
245,625
Morris, Arlene, DIR
Bought
06/09
37,500
0.00
Direct, Non Open Market
61.9
60,625
Prendergast, John K.A., DIR
Bought
06/09
75,000
0.00
Direct, Non Open Market
17.6
426,767
Rossetti, Angela, DIR
Bought
06/09
37,500
0.00
Direct, Non Open Market
31.1
120,625
Name, Title
Transaction
Transactions
During 2015
# of Shares
Price($)
Type
% of Holdings Traded
Now Holds
Deveer, Robert K., Jr., DIR
Bought
12/08
50,000
0.00
Direct, Non Open Market
18.1
275,726
Dunton, Alan W., DIR
Bought
12/08
40,000
0.00
Direct, Non Open Market
24.0
166,686
Horovitz, Zola P., DIR
Bought
12/08
50,000
0.00
Direct, Non Open Market
19.9
250,666
Hull, Joseph Stanley, DIR
Bought
12/08
50,000
0.00
Direct, Non Open Market
20.3
246,666
Morris, Arlene, DIR
Bought
12/08
20,000
0.00
Direct, Non Open Market
63.2
31,666
Prendergast, John K.A., DIR
Bought
12/08
100,000
0.00
Direct, Non Open Market
23.3
428,849
Rossetti, Angela, DIR
Bought
12/08
30,000
0.00
Direct, Non Open Market
29.5
101,666
Spana, Carl, CEO
Bought
12/08
325,000
0.00
Direct, Non Open Market
20.0
1,623,089
Wills, Stephen T., CFO
Bought
12/08
300,000
0.00
Direct, Non Open Market
20.2
1,483,852
© Vickers Stock Research Corporation 2016
Page 2
Recent PTN News
- Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones • PR Newswire (US) • 09/09/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 08:35:29 PM
- FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) • PR Newswire (US) • 08/28/2024 11:30:00 AM
- First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity • PR Newswire (US) • 08/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:01:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:31:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:31:01 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/25/2024 08:46:11 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 07/17/2024 03:14:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:32:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:32:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 08:31:16 PM
- Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds • PR Newswire (US) • 06/21/2024 12:00:00 PM
- Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) • PR Newswire (US) • 06/20/2024 11:30:00 AM
- Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity • PR Newswire (US) • 06/12/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:40:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 12:04:24 PM
- Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/15/2024 11:30:00 AM
- Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 • PR Newswire (US) • 05/09/2024 11:30:00 AM
- Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity • PR Newswire (US) • 05/02/2024 11:30:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM